Legend Biotech (LEGN) EBIT Margin (2019 - 2025)

Legend Biotech has reported EBIT Margin for 7 years, with the latest figure at 6.43% in Q4 2025.

• For the quarter ending Q4 2025, EBIT Margin rose 3609.0% year-over-year to 6.43%; the trailing twelve-month figure through Dec 2025 stood at 54.65% (down 234.0% YoY), and the FY2025 full-year result was 13.27%, up 3607.0% from the prior year.
• EBIT Margin for Q4 2025 stood at 6.43%, up from 15.96% in the prior quarter.
• The five-year high for EBIT Margin was 596.51% in Q2 2022, with the low at 97962.57% in Q1 2021.
• Historically, EBIT Margin has averaged 4679.86% across 5 years, with a median of 211.37% in 2023.
• Annual changes were most pronounced in 2021 — EBIT Margin tumbled 9845134 bps — and 2022, when it soared 9820825 bps.
• Legend Biotech's EBIT Margin stood at 230.36% in 2021, then surged by 72 bps to 395.35% in 2022, then slumped by 75 bps to 100.0% in 2023, then tumbled by 143 bps to 42.52% in 2024, then soared by 85 bps to 6.43% in 2025.
• The last three EBIT Margin figures came in at 6.43% (Q4 2025), 15.96% (Q3 2025), and 132.48% (Q2 2025), per Business Quant data.